Alexander disease is a rare and typically fatal neurodegenerative disease that results from heterozygous mutations in the gene encoding the type III intermediate filament protein GFAP. The pathological signature of the disorder is the Rosenthal fiber, a cytoplasmic inclusion containing intermediate filaments and small heat shock proteins that accumulates in astrocytes throughout the CMS. Prior investigations by our groups have let to the acceptance of GFAP mutations as the cause for nearly all cases of Alexander disease, and the rapid translation of this information to clinical practice as the standard for diagnosis. However, the mechanisms by which GFAP mutations cause astrocyte dysfunction and disease remain unclear. Based on results obtained during the previous grant period we have developed a hypothesis to guide experiments that emphasizes expression of elevated levels of GFAP in concert with induction of a cellular stress response and formation of inclusions as key elements of pathogenesis. The goals of this Program Project are to investigate molecular mechanisms and functional consequences of the stress response, to explore biochemical composition and downstream effects of inclusion body formation, and to identify and characterize genetic modifiers of disease phenotype. Our studies span genetic, biochemical, cellular, physiological, and morphological approaches to these questions. The Program will link five laboratories;three of these continue from the previous grant period, and two new groups join that bring novel approaches and techniques (physiology and Drosophila). The Program will promote a focussed effort on the role of glial filament dysfunction in disease, by fostering sharing of reagents, animals, and results among the five labs, through cross-fertilization of ideas, and by regular communication and meetings among laboratory members. These studies promise novel insights into the role of glial filaments in the cell biology of astrocytes, and the role of astrocytes in brain function and disease. PROJECT 1 Principal Investigator: Michael Brenner Title: Biochemistry and Genetics of Alexander Disease Description (provided by applicant): Glial fibrillary acidic protein (GFAP) is a structural protein found almost exclusively in astrocytes. Our laboratory recently found that mutations in the coding region of the GFAP gene cause Alexander disease (AxD), a rare but usually fatal disorder of the central nervous system. This disease is characterized by the presence of protein aggregates which have GFAP as a primary constituent. The purpose of this proposal is to develop additional information about the mechanism by which the GFAP mutations cause AxD.
In Aim 1 we will determine the composition of the RFs to obtain clues for the disease mechanism, an approach that has proved fruitful for other protein aggregate disorders. The aggregates will be partially purified, and their protein components identified by mass spectrometry.
In Aim 2 we will determine if the GFAP is abnormally deiminated or phosphorylated, two modifications of GFAP known to affect its polymerization and to be present in other neurodegenerative disorders.
In Aim 3 we will also determine whether the mutant form specifically accumulates in the aggregates. This will test the hypothesis that mutant GFAP is not toxic per se, but produces disease by causing GFAP accumulation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS042803-10
Application #
8284389
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Morris, Jill A
Project Start
2002-03-15
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$1,455,838
Indirect Cost
$141,072
Name
University of Wisconsin Madison
Department
Pediatrics
Type
Other Domestic Higher Education
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Wang, Liqun; Hagemann, Tracy L; Messing, Albee et al. (2016) An In Vivo Pharmacological Screen Identifies Cholinergic Signaling as a Therapeutic Target in Glial-Based Nervous System Disease. J Neurosci 36:1445-55
Heaven, Michael R; Flint, Daniel; Randall, Shan M et al. (2016) Composition of Rosenthal Fibers, the Protein Aggregate Hallmark of Alexander Disease. J Proteome Res 15:2265-82
Wang, Liqun; Hagemann, Tracy L; Kalwa, Hermann et al. (2015) Nitric oxide mediates glial-induced neurodegeneration in Alexander disease. Nat Commun 6:8966
Olabarria, Markel; Putilina, Maria; Riemer, Ellen C et al. (2015) Astrocyte pathology in Alexander disease causes a marked inflammatory environment. Acta Neuropathol 130:469-86
LaPash Daniels, Christine M; Paffenroth, Elizabeth; Austin, Elizabeth V et al. (2015) Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease. PLoS One 10:e0138132
Sosunov, Alexander A; McGovern, Robert A; Mikell, Charles B et al. (2015) Epileptogenic but MRI-normal perituberal tissue in Tuberous Sclerosis Complex contains tuber-specific abnormalities. Acta Neuropathol Commun 3:17
Jany, Paige L; Agosta, Guillermo E; Benko, William S et al. (2015) CSF and Blood Levels of GFAP in Alexander Disease(1,2,3). eNeuro 2:
Minkel, Heather R; Anwer, Tooba Z; Arps, Kara M et al. (2015) Elevated GFAP induces astrocyte dysfunction in caudal brain regions: A potential mechanism for hindbrain involved symptoms in type II Alexander disease. Glia 63:2285-97
Brenner, Michael; Messing, Albee (2015) A new mutation in GFAP widens the spectrum of Alexander disease. Eur J Hum Genet 23:1-2
Cotrina, Maria Luisa; Chen, Michael; Han, Xiaoning et al. (2014) Effects of traumatic brain injury on reactive astrogliosis and seizures in mouse models of Alexander disease. Brain Res 1582:211-9

Showing the most recent 10 out of 60 publications